Erin Quirk, Terns Pharmaceuticals president and head of R&D

Terns Phar­ma­ceu­ti­cals touts mid-stage suc­cess for NASH drug, stock falls

Terns Phar­ma­ceu­ti­cals said a high dose of its ex­per­i­men­tal oral NASH treat­ment helped re­duce liv­er fat in a Phase IIa tri­al.

The Fos­ter City, CA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.